Skip to content
DraconiticResearch
Search Sources API
190,869 studies31 sourcesUpdated 6 min ago
Peer-reviewedCC BY-NCOncoTargets and therapy

Long-Noncoding RNA PCAT6 Aggravates Osteosarcoma Tumourigenesis via the MiR-143-3p/ZEB1 Axis [Retraction].

Abstract

[This retracts the article DOI: 10.2147/OTT.S258415.].

Related

  1. Statement of Retraction: Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.
    Cancer biology & therapyPeer-reviewedCC BYFull textOncologyEurope PMC
  2. High-Calorie Diet Aggravates Lipopolysaccharide-Induced Pulmonary Inflammation in Juvenile Mice: Association of Acetate-Mediated Macrophage Polarization with AMPK/YAP Signaling
    Futongyu Sun, Hui Liu, Shuxuan Li +6
    NutrientsPeer-reviewedCC BYFull textNutritionEurope PMC
  3. Gut epithelial aryl hydrocarbon receptor deficiency aggravates fungal dysbiosis-mediated neutrophilic allergic airway disease in mice
    Ting Wang, Chao Lei, Zhishan Xu +10
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textPhysiologyCrossref
  4. Estradiol deficiency aggravates AngII-induced vascular remodeling by failing to inhibit GRK2 through ERα-mediated autophagy
    Miao-Jin Ji, Ni-na Song, Joseph Adu-Amankwaah +7
    Communications BiologyPeer-reviewedCC BY-NC-ND 4.0Full textCardiovascular medicineCrossref
  5. Statement of Retraction: Fischer's oligopeptide ratio in ischemic hypoxia: prophylactic amendment of sophoretin and melatonin supplementation.
    Future science OAPeer-reviewedCC BYFull textNeurologyEurope PMC
BibTeX
@article{anon2026longnoncoding,
  title = {{Long-Noncoding RNA PCAT6 Aggravates Osteosarcoma Tumourigenesis via the MiR-143-3p/ZEB1 Axis [Retraction].}},
  journal = {OncoTargets and therapy},
  year = {2026},
  month = oct,
  doi = {10.2147/ott.s663553},
  url = {https://europepmc.org/article/MED/42936088},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Long-Noncoding RNA PCAT6 Aggravates Osteosarcoma Tumourigenesis via the MiR-143-3p/ZEB1 Axis [Retraction].
PY  - 2026
DA  - 2026/10/21
JO  - OncoTargets and therapy
DO  - 10.2147/ott.s663553
UR  - https://europepmc.org/article/MED/42936088
AB  - [This retracts the article DOI: 10.2147/OTT.S258415.].
SN  - 1178-6930
ER  -